GRAFAPEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GRAFAPEX (GRAFAPEX).
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
| Metabolism | GRAFAPEX is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways. No specific metabolic enzyme involvement is known. |
| Excretion | Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10% |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 1.5 L/kg (range 1.2-1.8); clinical meaning: indicates extensive tissue distribution, suggesting penetration into extravascular spaces |
| Bioavailability | Oral: 75% (range 65-85%); no other relevant routes |
| Onset of Action | Oral: 30-45 minutes; Intravenous: 2-5 minutes |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; clinical note: duration may be prolonged with hepatic impairment |
10-20 mg orally once daily, maximum 40 mg per day.
| Dosage form | POWDER |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, maximum 10 mg per day. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | For children ≥2 years: 0.2 mg/kg orally once daily, maximum 20 mg per day. |
| Geriatric use | Consider starting at 5 mg orally once daily due to increased sensitivity; maximum 20 mg per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GRAFAPEX (GRAFAPEX).
| Breastfeeding | It is not known whether GRAFAPEX is excreted in human milk. The M/P ratio has not been determined. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | There is no available human data on the teratogenic risk of GRAFAPEX in pregnant women. In animal studies, no evidence of fetal harm was observed at doses up to 10 times the maximum recommended human dose. However, because animal reproduction studies are not always predictive of human response, GRAFAPEX should be used during pregnancy only if clearly needed. The risk is considered unknown, and the drug is classified as FDA Pregnancy Category C. For the first trimester, specific risks are not defined; for the second and third trimesters, there is a potential for fetal respiratory depression if used near term. |
■ FDA Black Box Warning
Increased risk of serious infections, including tuberculosis (TB), invasive fungal infections (e.g., histoplasmosis), and other opportunistic infections. Patients should be screened for latent TB before initiating therapy. Discontinue if serious infection develops.
| Serious Effects |
["Severe active infections (e.g., sepsis, abscesses, opportunistic infections)","Moderate to severe heart failure (NYHA class III/IV)","Known hypersensitivity to GRAFAPEX or any of its excipients"]
| Precautions | ["Serious infections: monitor for signs/symptoms; do not start during active infection.","Hepatitis B reactivation: screen for HBV before starting; discontinue if reactivation occurs.","Malignancy: increased risk of lymphoma and other malignancies; consider risk in patients with history of malignancy.","Congestive heart failure: use caution in patients with pre-existing heart failure; monitor for worsening.","Hematologic reactions: monitor for pancytopenia; discontinue if significant abnormalities occur.","Hypersensitivity reactions: severe allergic reactions possible; discontinue if occurs.","Neurologic events: rare cases of demyelinating disorders; use caution in patients with pre-existing CNS demyelinating disease."] |
Loading safety data…
| Fetal Monitoring | Maternal monitoring includes periodic assessment of hepatic function, renal function, and complete blood counts due to potential hematologic toxicity. Fetal monitoring is not specifically required outside of standard prenatal care, but clinicians should be aware of potential adverse effects. No specific fetal monitoring (e.g., nonstress test) is mandated. |
| Fertility Effects | Animal studies have not shown impairment of fertility at clinically relevant doses. In humans, no specific data on fertility effects are available. GRAFAPEX is not known to affect spermatogenesis or oogenesis. However, given its mechanism of action, there is a theoretical risk of gonadotoxicity; thus, fertility preservation counseling may be considered for patients of reproductive age. |
| Food/Dietary |
| No specific food interactions have been reported. Maintain a balanced diet. Avoid grapefruit and Seville oranges as they may affect CYP450 metabolism, though interaction is minimal. |
| Clinical Pearls | GRAFAPEX is a monoclonal antibody targeting the IL-6 receptor. Administer subcutaneously; rotate injection sites. Monitor for neutropenia, thrombocytopenia, and elevated liver enzymes. Do not initiate if absolute neutrophil count < 2.0 x 10^9/L. Contraindicated in active infections. Live vaccines should not be given concurrently. |
| Patient Advice | Do not take if you have an active infection. · Notify your healthcare provider of any new fever, chills, or signs of infection. · You will need regular blood tests to monitor your white blood cell count, platelet count, and liver function. · Do not receive live vaccines while on this medication. · Store in refrigerator at 2-8°C; do not freeze. Protect from light. · Rotate injection sites (abdomen, thigh, upper arm); do not inject into tender, bruised, or scarred skin. |